Stage (next event)
Catalyst Info & Data Links
TITLE: FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy NDA Filing
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
03-27-2020 Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
MECHANISM OF ACTION
FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate.
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post